What it is
Regulatory status: prescription medication
Mechanism evidence: human
Febuxostat inhibits xanthine oxidase, lowering production of uric acid. It treats chronic hyperuricemia in gout; it is not a medicine for asymptomatic hyperuricemia.
What it is, why people use it, the evidence, and what to know before trying it.
Regulatory status: prescription medication
Mechanism evidence: human
Febuxostat effectively lowers urate but is a prescription gout medicine with material cardiovascular and interaction considerations. Its place in therapy requires clinician judgment rather than protocol copying.
Confidence: strong
Contraindications, interactions and clinical cautions from reviewed sources.
US labeling carries a boxed warning about cardiovascular death. Liver effects and gout flares require monitoring, and the drug is contraindicated with azathioprine or mercaptopurine.
This review does not automatically apply to:
Public protocols that include Febuxostat. Open one to see the full context and source.
Brand variants reported in public protocols. Private entries are excluded, and inclusion is not an endorsement.
Continue into interventions that appear alongside this one.